Lower gastrointestinal bleeding medical therapy
|
Lower gastrointestinal bleeding Microchapters |
|
Differentiating Lower gastrointestinal bleeding from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Management |
|
Surgery |
|
Case Studies |
|
Lower gastrointestinal bleeding medical therapy On the Web |
|
American Roentgen Ray Society Images of Lower gastrointestinal bleeding medical therapy |
|
Risk calculators and risk factors for Lower gastrointestinal bleeding medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Muhammad Saad, M.D.[2] Aditya Ganti M.B.B.S. [3]
Medical Therapy
No drug has been shown to stop acute colonic bleeding. Medical therapy in acute lower gastrointestinal bleeding (LGIB) is therefore supportive. Its goals are to stabilize the patient and allow localization and definitive endoscopic, angiographic, or surgical hemostasis. Most LGIB stops spontaneously.[1] Medical management has five parts:
- Risk stratification to decide between discharge and admission.
- Crystalloid resuscitation before any procedure.
- Restrictive red cell transfusion.
- Selective management of antithrombotics, with reversal reserved for life-threatening bleeding that does not respond to resuscitation.
- Therapy directed at the cause, chiefly for transfusion-dependent angiodysplasia.
Restarting antithrombotics after bleeding stops is covered in secondary prevention. Endoscopic and angiographic hemostasis are covered in surgery and procedural therapy.
Triage and Disposition
- ACG 2023 (conditional recommendation, low-quality evidence): use a risk tool such as an Oakland score ≤8 to identify low-risk patients for early discharge and outpatient evaluation. The score supplements clinical judgment and does not replace it.[1]
- BSG 2019 and ESGE strongly recommend Oakland ≤8 to select patients with self-limited bleeding and no adverse features for outpatient workup.[1]
- In real-world practice, many low-risk patients are still admitted, mainly because of comorbidity.[2]
- A low score should not override ongoing bleeding, hemodynamic instability (shock index), or significant comorbidity.[1][2]
- In a multicenter Japanese cohort (CODE BLUE-J, n = 8,956), 30-day rebleeding was 25.5% in colonic diverticular bleeding despite an Oakland score ≤8. Apply the discharge threshold cautiously when diverticular bleeding is suspected.[3]
Hemodynamic Resuscitation
- ACG 2023: patients who are hemodynamically unstable or actively bleeding should receive IV crystalloid to normalize blood pressure and heart rate before endoscopic evaluation or any other procedure.[1]
- Standard practice includes two large-bore IV lines, balanced crystalloid, and early type and crossmatch.
- In major hemorrhage, hemoglobin alone should not guide transfusion; use the institutional massive transfusion protocol.[4]
- In patients taking a direct oral anticoagulant (DOAC), adequate resuscitation also supports renal clearance of the drug.[5]
Transfusion
| Scenario | Threshold | Strength / source |
|---|---|---|
| Hemodynamically stable LGIB | Transfuse packed red blood cells at Hb <7 g/dL | ACG 2023: conditional recommendation, low-quality evidence[1] |
| Pre-existing cardiovascular disease | BSG/AP&T: trigger 8 g/dL, target ≥10 g/dL | No LGIB-specific RCT. The NEJM review suggests considering 9 g/dL.[6][7] |
| Acute myocardial infarction with anemia | Once bleeding is controlled, consider liberal transfusion at Hb <10 g/dL. MINT excluded patients with uncontrolled bleeding (only 13% had recent bleeding), so evidence for active major LGIB is lacking.[8] | In MINT, the restrictive strategy showed a non-significant trend toward more 30-day death or MI (RR 1.15; 95% CI 0.99–1.34).[8] AABB 2025: conditional recommendation (low-certainty evidence) for transfusion at Hb <10 g/dL.[9] 2025 ACC/AHA ACS guideline: transfusion to Hb ≥10 g/dL may be reasonable (COR 2b, LOE B-R).[10] |
| Hemorrhagic shock or major ongoing bleeding | Liberal strategy via massive transfusion protocol | These patients were excluded from the restrictive-strategy RCTs[1][4] |
| Thrombocytopenia during severe LGIB | Maintain platelets >30 × 109/L; consider >50 × 109/L if an endoscopic procedure is required | ACG 2023 key concept (no LGIB-specific data)[1] |
| Antiplatelet therapy without thrombocytopenia | No routine platelet transfusion | ACG 2023: no rebleeding benefit and higher mortality in a case-control study.[1] ACG–CAG 2022: suggests against (conditional, very low certainty).[11] |
- Evidence base: the evidence is largely extrapolated from upper GI bleeding.
- In UGIB, a 7 vs. 9 g/dL threshold improved 6-week survival.
- A meta-analysis of 5 RCTs found lower mortality (RR 0.65) and less rebleeding (RR 0.58) with restrictive transfusion.[1]
- LGIB-specific data: in a post hoc analysis of the UK national audit, liberal transfusion gave no rebleeding benefit (OR 0.89). Mortality trended in favor of the restrictive strategy (OR 0.54, 95% CI 0.3–1.1).[1]
Antithrombotic Management During Active Bleeding
General Approach
- Minor bleeding at low risk of intervention (e.g., Oakland ≤8): the anticoagulant may be continued if clinically necessary.[1]
- Significant bleeding requiring admission: hold the anticoagulant on admission.[1]
- Most DOAC-associated LGIB resolves with drug discontinuation, resuscitation, and time for clearance.[1]
- Reversal decisions should be multidisciplinary and should weigh ongoing hemorrhage against thrombotic risk.[5]
- Guideline disagreement on reversal:
- The ACG LGIB guideline (2023) suggests targeted reversal for the small subset of patients with life-threatening LGIB that does not respond to resuscitation and drug cessation, when the DOAC was taken within 24 hours (conditional, very low quality).[1]
- The ACG–CAG antithrombotic guideline (2022) suggests against each of the following (all conditional, very low certainty):[11]
- FFP and routine vitamin K in patients on warfarin.
- PCC for DOACs.
- Idarucizumab for dabigatran.
- Andexanet alfa for rivaroxaban or apixaban.
- Platelet transfusion in patients on antiplatelet agents.
- If reversal is pursued in warfarin patients, ACG–CAG suggests PCC over FFP.[11]
- ACG–CAG made no recommendation for or against PCC vs. placebo in warfarin patients. Reversal can still be considered for truly life-threatening bleeding.[11][12]
- Do not delay endoscopy to correct a modestly elevated INR (≤2.5). Endoscopic therapy can be performed safely at INR ≤2.5, and the INR at presentation does not predict rebleeding. Reversal agents are discouraged unless the patient remains unstable despite resuscitation.[1][13]
Reversal by Drug Class
| Anticoagulant | Agent and dose | Key evidence and cautions |
|---|---|---|
| Warfarin (vitamin K antagonist) | 4-factor prothrombin complex concentrate (4F-PCC), dosed by INR and actual body weight up to 100 kg, per label:[14] INR 2–<4: 25 U/kg (max 2,500 U) INR 4–6: 35 U/kg (max 3,500 U) INR >6: 50 U/kg (max 5,000 U) Repeat dosing is not supported by the label.[14] A low fixed dose (1,000 U for major bleeding) is described in ACC guidance.[5] Plus vitamin K 5–10 mg by slow IV infusion (label: give concurrently, as a single PCC dose), because factor VII from PCC lasts only hours.[14][15][16] |
Reverse only in life-threatening LGIB with INR well above the therapeutic range (ACG 2023: conditional, very low quality).[1] PCC is preferred over FFP: faster INR correction, less volume overload, and lower all-cause mortality.[1] Recheck the INR after infusion. Boxed warning: arterial and venous thromboembolism. Contraindications: anaphylaxis to any component (including heparin), DIC, known heparin-induced thrombocytopenia.[14] |
| Dabigatran | Idarucizumab 5 g IV, given as two 2.5 g doses no more than 15 minutes apart.[17] An additional 5 g may be considered for recurrent bleeding with elevated coagulation parameters.[18] If idarucizumab is unavailable: hemodialysis, or PCC/aPCC.[19] |
In the RE-VERSE AD GI subgroup (43 of 137 patients had LGIB), bleeding stopped within 24 hours in 68.7%. In a national cohort, idarucizumab was associated with more transfusion and higher cost, with no mortality difference.[1] Each 5 g dose contains about 4 g sorbitol; caution in hereditary fructose intolerance. Dabigatran may be restarted ≥24 hours after reversal once hemostasis allows. Usable in pregnancy when clearly needed.[18] In chronic kidney disease, clinically relevant dabigatran levels may persist beyond the 24-hour window used by ACG. |
| Apixaban, rivaroxaban (factor Xa inhibitors) | U.S. (off-label; optimal dose undefined): 4F-PCC 50 U/kg IV or a fixed 2,000 U (2020 ACC pathway).[15] The 2023 ACC/AHA AF guideline lists 2,000 U once or 25–50 U/kg.[20] Trials comparing doses are ongoing.[16] Activated PCC 50 U/kg if 4F-PCC is unavailable.[5][19] Outside the U.S.: andexanet alfa where licensed (EMA conditional approval, renewed April 2025; UK), for apixaban and rivaroxaban only, not edoxaban.[16][21] |
PCC benefit for factor Xa inhibitors is unproven. ACG 2023 states PCC has no definitive role,[1] and ACG–CAG suggests against PCC for DOAC-associated GI bleeding.[11] Andexanet alfa was withdrawn from U.S. sale effective 22 December 2025, after the FDA concluded that its risks, including excess thromboembolism (ANNEXA-I: 10.3% vs. 5.6%), outweighed its benefits.[16][21][22] Andexanet interferes with routine anti-Xa assays and produces falsely high drug levels.[16][23] |
- Laboratory testing: PT and aPTT are unreliable for DOACs. A normal value does not exclude a clinically relevant apixaban or rivaroxaban level. Use calibrated anti-Xa levels where available.[1]
- Rebound: DOAC levels can rebound after reversal and cause recurrent bleeding, so continue monitoring.[17]
- Activated charcoal: generally avoid in GI bleeding. General anticoagulant guidance permits activated charcoal when the last DOAC dose was within 2–4 hours,[24][20] but in GI bleeding it severely compromises endoscopic visualization and complicates airway management if the patient deteriorates. Reserve it for acute DOAC overdose.[17]
- While anticoagulants are held, use mechanical venous thromboembolism prophylaxis and plan resumption early (see secondary prevention).
Antiplatelet Agents
- Aspirin for secondary prevention: continue during hospitalization in most patients. Consider temporary interruption only for severe or ongoing bleeding, with multidisciplinary input if thrombotic risk is high.[1] If aspirin is interrupted, ACG–CAG suggests resuming it on the day hemostasis is endoscopically confirmed.[12]
- Aspirin for primary prevention: hold.[1]
- Dual antiplatelet therapy: continue aspirin and hold the P2Y12 inhibitor. With a coronary stent placed within the past year, decide as a multidisciplinary team and resume the P2Y12 inhibitor within a maximum of 5 days because of stent thrombosis risk.[1]
- No platelet transfusion to reverse antiplatelet effect in patients without thrombocytopenia.[1][11]
- Long-term decisions and resumption timing are covered in secondary prevention.
Tranexamic Acid: Not Recommended
- Tranexamic acid should not be used for GI bleeding outside of clinical trials.[25][26]
- HALT-IT (n = 12,009) gave 1 g IV over 10 minutes, then 3 g over 24 hours. Only 11% of participants had suspected lower GI bleeding and 45% had suspected variceal bleeding, so application to LGIB is by extrapolation.[25]
- Death from bleeding at 5 days: 4% in both arms (RR 0.99).
- More venous thromboembolism with TXA (0.8% vs. 0.4%; RR 1.85).
- More seizures with TXA (0.6% vs. 0.4%; RR 1.73).
- Not cost-effective.[26]
- These results supersede earlier meta-analyses of small trials that suggested a mortality benefit but were prone to selection bias.[26]
Drug Therapy by Cause
Angiodysplasia
Indicated for transfusion-dependent bleeding or recurrent bleeding despite endoscopic therapy.
Scope note: the randomized evidence comes predominantly from small-intestinal angiodysplasia; OCEAN later expanded enrollment to lesions outside the small bowel, so use for colonic angiodysplasia is extrapolated.[27][28] Both octreotide LAR and thalidomide are off-label for this indication.
Hormonal (estrogen–progesterone) therapy is not recommended. In a multicenter double-blind RCT (n = 72; ethinyl estradiol plus norethisterone for ≥1 year), treatment failure was 39% vs. 46% with placebo, a non-significant difference. Bleeding episodes and transfusion requirements did not differ, and severe adverse events were similar (2 vs. 1). The trial enrolled noncirrhotic patients with angiodysplasia anywhere in the GI tract.[29][30][31]
| Agent | Regimen | Evidence | Adverse effects / cautions |
|---|---|---|---|
| Octreotide LAR (preferred initial agent; off-label) | 40 mg IM every 28 days (OCEAN regimen), gluteal IM only[32][33] The label restricts the depot to patients who have tolerated subcutaneous octreotide. Levels are not therapeutic for 10–14 days after the first injection. The label advises starting at 10 mg in dialysis or cirrhosis.[33] |
OCEAN RCT (open-label, n = 62; entry required ≥4 RBC units and/or IV iron infusions in the prior year) vs. standard care:[32] Transfusion units (RBC units + IV iron infusions) over 1 year: 11.0 vs. 21.2 (difference 10.2; 95% CI 2.4–18.1) RBC units alone: 8.2 vs. 17 Response (≥50% fewer transfusions): 61% vs. 19%; NNT 2 for good response; benefit within 4 weeks Fewer endoscopies and less fatigue[28] |
Loose stools, cholelithiasis, flatulence, injection-site reactions; 5% discontinued. Cholangitis and hypoglycemia have been reported.[28][34] Monitoring: glucose, gallbladder symptoms, TSH and T4, vitamin B12, and heart rate (bradycardia). Interactions: adjust insulin or oral antidiabetic drugs according to glucose; additive bradycardia with beta-blockers.[33] |
| Somatostatin analogues (class) | IPD meta-analysis authors recommended octreotide LAR 10 mg every 28 days[34] | IPD meta-analysis (n = 212): transfusion IRR 0.18. Octreotide performed better than lanreotide; response was worse for gastric lesions.[34] | As above |
| Thalidomide (alternative or after octreotide failure; off-label) | 100 mg or 50 mg orally once daily at bedtime for 4 months[35] (bedtime dosing because somnolence is common)[36] Starting at 50 mg and increasing to 100 mg, depending on response and side effects, is reasonable.[37] Do not start if ANC <750/mm3.[36] |
Multicenter double-blind RCT (n = 150; small-intestinal angiodysplasia; antithrombotic users excluded):[35] ≥50% reduction in bleeding episodes: 68.6% (100 mg), 51.0% (50 mg), 16.0% (placebo) Transfusion needed: 17.6%, 24.5%, 62.0% Of 42 thalidomide-treated patients without rebleeding in the year after treatment, 20 rebled over the following 3–27 months, so retreatment may be needed. Optimal dose and course duration are uncertain.[35][37] Earlier single-center open-label RCT (thalidomide 25 mg four times daily vs. iron 100 mg daily): response 69.2% vs. 3.8% as reported by Laine; 71% vs. 4% (20/28 vs. 1/27) as reported by Gerson 2015.[37][30] |
Boxed warnings: embryofetal toxicity (contraindicated in pregnancy; REMS required) and VTE.[36] The VTE warning conflicts with withholding pharmacologic thromboprophylaxis in patients who are bleeding; weigh this before starting. In the RCT: constipation, somnolence, limb numbness, peripheral edema, dizziness, and elevated liver enzymes, mostly mild to moderate.[35] Other: peripheral neuropathy and bradycardia;[36] bowel perforation, reported across thalidomide RCTs;[38] possible link to ischemic heart disease.[39] |
- The octreotide-first sequence reflects better adherence (one injection a month vs. daily pills) and thalidomide's toxicity (teratogenicity, VTE, neuropathy), not comparative efficacy. No head-to-head trial exists, and the thalidomide RCT is larger and double-blind.[37]
- OCEAN population: 79% were taking antithrombotics. Patients with liver disease, hereditary hemorrhagic telangiectasia, or an LVAD were excluded.[28]
- Greatest benefit is seen in patients with more lesions and higher transfusion requirements.[28]
- Iron: IV or oral iron repletion for all patients.
- Whether acute octreotide infusion helps during an active bleed is unknown.[28]
Other Causes
- Infectious colitis and inflammatory bowel disease: treat the underlying disease (see the respective topic pages).
- Radiation proctitis and hemorrhoids: see the respective topic pages and procedural therapy.
Summary of Recommendations
- Calculate the shock index and Oakland score. If the score is ≤8, bleeding has stopped, and there are no adverse features, consider discharge with outpatient colonoscopy. Be cautious when diverticular bleeding is suspected.[1][3]
- Resuscitate with crystalloid to normal hemodynamics before colonoscopy or CT angiography.[1]
- Transfuse at Hb <7 g/dL in stable patients. Use a higher trigger with cardiovascular disease, and a liberal strategy (Hb <10 g/dL) in acute MI once bleeding is controlled. Use a massive transfusion protocol in shock.[1][8][9]
- Hold anticoagulants in significant bleeding. Reserve reversal for life-threatening bleeding that does not respond to resuscitation and drug cessation (ACG–CAG suggests against routine reversal):[1][11]
- Warfarin: 4F-PCC plus IV vitamin K.
- Dabigatran: idarucizumab.
- Factor Xa inhibitors in the U.S.: off-label 4F-PCC, with unproven benefit and undefined optimal dose.
- Avoid activated charcoal in GI bleeding except for acute DOAC overdose.[17]
- Do not transfuse platelets to reverse antiplatelet agents in patients without thrombocytopenia.[11]
- Do not give tranexamic acid.[25]
- Do not delay endoscopy to correct an INR ≤2.5.[1]
- For transfusion-dependent angiodysplasia, consider off-label octreotide LAR (40 mg every 28 days in OCEAN) plus iron, with thalidomide as the alternative. Do not use hormonal therapy.[32][35][29]
Areas of Uncertainty
- Whether to reverse at all: ACG 2023 supports targeted reversal in life-threatening LGIB. ACG–CAG 2022 suggests against FFP, vitamin K, PCC for DOACs, idarucizumab, and andexanet, and makes no recommendation on PCC vs. placebo for warfarin.[1][11]
- Vitamin K: ACG–CAG suggests against routine use in GI bleeding (conditional), but vitamin K is paired with PCC when PCC is given for life-threatening bleeding.[11][16]
- Transfusion with cardiovascular disease: trigger 8 g/dL with target ≥10 g/dL (BSG/AP&T) vs. consider 9 g/dL (NEJM review). In acute MI, MINT and AABB 2025 favor a liberal strategy (Hb <10 g/dL), but MINT excluded uncontrolled bleeding. There is no LGIB-specific RCT.[6][7][8][9]
- Factor Xa inhibitor reversal: PCC benefit and optimal dose are unproven, and andexanet alfa was withdrawn from the U.S. in December 2025.[1][16][21]
- Oakland-guided discharge: prospective multicenter validation is lacking, and rebleeding after discharge may be substantial in diverticular bleeding.[1][3]
- Octreotide dose: 40 mg every 28 days (OCEAN) vs. 10 mg every 28 days (recommended by the IPD meta-analysis authors), with no head-to-head comparison. The relative efficacy of thalidomide vs. somatostatin analogues is untested.[37]
- Colonic angiodysplasia: drug efficacy is extrapolated from predominantly small-bowel data.[27]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 1.25 1.26 1.27 1.28 1.29 1.30 1.31 1.32 Sengupta N, Feuerstein JD, Jairath V; et al. (2023). "Management of patients with acute lower gastrointestinal bleeding: an updated ACG guideline". Am J Gastroenterol. 118 (2): 208–231. doi:10.14309/ajg.0000000000002130.
- ↑ 2.0 2.1 Çetin MF, Gönüllü ME, Yekenkurul E, Gürsoy F (2026). "Clinical utility of the Oakland score in rectal bleeding: implications for admission decisions and cost efficiency". Int J Colorectal Dis. 41 (1): 88. doi:10.1007/s00384-026-05128-4.
- ↑ 3.0 3.1 3.2 Kinjo K, Aoki T, Kobayashi K; et al. (2025). "Validation of British Society of Gastroenterology guidelines for acute lower GI bleeding from 8956 cases in Japan". Gastrointest Endosc. 101 (6): 1131–1144.e10. doi:10.1016/j.gie.2024.11.020. PMID 39557205 Check
|pmid=value (help). - ↑ 4.0 4.1 Stanworth SJ, Dowling K, Curry N; et al. (2022). "Haematological management of major haemorrhage: a British Society for Haematology guideline". Br J Haematol. 198 (4): 654–667. doi:10.1111/bjh.18275.
- ↑ 5.0 5.1 5.2 5.3 Milling TJ, Refaai MA, Sengupta N (2021). "Anticoagulant reversal in gastrointestinal bleeding: review of treatment guidelines". Dig Dis Sci. 66 (11): 3698–3714. doi:10.1007/s10620-020-06728-y.
- ↑ 6.0 6.1 Alali AA, Almadi MA, Barkun AN (2024). "Review article: advances in the management of lower gastrointestinal bleeding". Aliment Pharmacol Ther. 59 (5): 632–644. doi:10.1111/apt.17859.
- ↑ 7.0 7.1 Gralnek IM, Neeman Z, Strate LL (2017). "Acute lower gastrointestinal bleeding". N Engl J Med. 376 (11): 1054–1063. doi:10.1056/NEJMcp1603455.
- ↑ 8.0 8.1 8.2 8.3 Carson JL, Brooks MM, Hébert PC; et al. (2023). "Restrictive or liberal transfusion strategy in myocardial infarction and anemia". N Engl J Med. 389 (26): 2446–2456. doi:10.1056/NEJMoa2307983.
- ↑ 9.0 9.1 9.2 Pagano MB, Stanworth SJ, Dennis J; et al. (2025). "Red cell transfusion in acute myocardial infarction: AABB international clinical practice guidelines". Ann Intern Med. 178 (10): 1469–1477. doi:10.7326/ANNALS-25-00706.
- ↑ Rao SV, O'Donoghue ML, Ruel M; et al. (2025). "2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes". J Am Coll Cardiol. 85 (22): 2135–2237. doi:10.1016/j.jacc.2024.11.009.
- ↑ 11.00 11.01 11.02 11.03 11.04 11.05 11.06 11.07 11.08 11.09 Abraham NS, Barkun AN, Sauer BG; et al. (2022). "American College of Gastroenterology–Canadian Association of Gastroenterology clinical practice guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period". Am J Gastroenterol. 117 (4): 542–558. doi:10.14309/ajg.0000000000001627.
- ↑ 12.0 12.1 Lichtenstein DR, Dharmadhikari ND (2022). "ACG–CAG provided suggestions for periendoscopic management of anticoagulants and antiplatelets". Ann Intern Med. 175 (7): JC74. doi:10.7326/J22-0041.
- ↑ Hawks MK (2024). "Management of acute lower GI bleeding: guidelines from the American College of Gastroenterology". Am Fam Physician. 109 (3): 284–285.
- ↑ 14.0 14.1 14.2 14.3 Kcentra (prothrombin complex concentrate, human) prescribing information. CSL Behring. DailyMed.
- ↑ 15.0 15.1 Tomaselli GF, Mahaffey KW, Cuker A; et al. (2020). "2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants". J Am Coll Cardiol. 76 (5): 594–622. doi:10.1016/j.jacc.2020.04.053.
- ↑ 16.0 16.1 16.2 16.3 16.4 16.5 16.6 Rocca B, Ten Cate H (2026). "Antidotes for anticoagulation reversal". N Engl J Med. 394 (22): 2235–2254. doi:10.1056/NEJMra2506021.
- ↑ 17.0 17.1 17.2 17.3 Benamouzig R, Guenoun M, Deutsch D, Fauchier L (2022). "Review article: gastrointestinal bleeding risk with direct oral anticoagulants". Cardiovasc Drugs Ther. 36 (5): 973–989. doi:10.1007/s10557-021-07211-0.
- ↑ 18.0 18.1 Praxbind (idarucizumab) prescribing information. Boehringer Ingelheim. DailyMed.
- ↑ 19.0 19.1 Kumbhani DJ, Armbruster AL, Cheng RK; et al. (2026). "Direct oral anticoagulants in primary and secondary prevention of thrombotic events: 2026 ACC scientific statement". J Am Coll Cardiol. doi:10.1016/j.jacc.2026.05.033.
- ↑ 20.0 20.1 Joglar JA, Chung MK; et al. (2024). "2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation". J Am Coll Cardiol. 83 (1): 109–279. doi:10.1016/j.jacc.2023.08.017.
- ↑ 21.0 21.1 21.2 Buka RJ, Arachchillage DJ, Bagot CN; et al. (2026). "Use of andexanet alfa: a British Society for Haematology position statement". Br J Haematol. 208 (6): 1939–1941. doi:10.1111/bjh.70509.
- ↑ U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (andexanet alfa listing).
- ↑ Rossaint R, Afshari A, Bouillon B; et al. (2023). "The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition". Crit Care. 27 (1): 80. doi:10.1186/s13054-023-04327-7.
- ↑ Van Gelder IC, Rienstra M, Bunting KV; et al. (2024). "2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)". Eur Heart J. 45 (36): 3314–3414. doi:10.1093/eurheartj/ehae176.
- ↑ 25.0 25.1 25.2 HALT-IT Trial Collaborators (2020). "Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial". Lancet. 395 (10241): 1927–1936. doi:10.1016/S0140-6736(20)30848-5. PMID 32563378 Check
|pmid=value (help). - ↑ 26.0 26.1 26.2 Roberts I, Shakur-Still H, Afolabi A; et al. (2021). "A high-dose 24-hour tranexamic acid infusion for the treatment of significant gastrointestinal bleeding: HALT-IT RCT". Health Technol Assess. 25 (58): 1–86. doi:10.3310/hta25580. PMID 34663491 Check
|pmid=value (help). - ↑ 27.0 27.1 Grooteman KV, van Geenen EJ, Drenth JP (2016). "Multicentre, open-label, randomised, parallel-group, superiority study to compare the efficacy of octreotide therapy 40 mg monthly versus standard of care in patients with refractory anaemia due to gastrointestinal bleeding from small bowel angiodysplasias: a protocol of the OCEAN trial". BMJ Open. 6 (9): e011442. doi:10.1136/bmjopen-2016-011442.
- ↑ 28.0 28.1 28.2 28.3 28.4 28.5 Flynn DJ, Feuerstein JD (2024). "In transfusion-dependent, angiodysplasia-related anemia, adding octreotide to usual care reduced transfusions at 1 y". Ann Intern Med. 177 (6): JC69. doi:10.7326/ANNALS-24-00517-JC.
- ↑ 29.0 29.1 Junquera F, Feu F, Papo M; et al. (2001). "A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia". Gastroenterology. 121 (5): 1073–1079. doi:10.1053/gast.2001.28650.
- ↑ 30.0 30.1 Gerson LB, Fidler JL, Cave DR, Leighton JA (2015). "ACG clinical guideline: diagnosis and management of small bowel bleeding". Am J Gastroenterol. 110 (9): 1265–1287. doi:10.1038/ajg.2015.246.
- ↑ Sami SS, Al-Araji SA, Ragunath K (2014). "Review article: gastrointestinal angiodysplasia – pathogenesis, diagnosis and management". Aliment Pharmacol Ther. 39 (1): 15–34. doi:10.1111/apt.12527.
- ↑ 32.0 32.1 32.2 Goltstein LCMJ, Grooteman KV, Bernts LHP; et al. (2024). "Standard of care versus octreotide in angiodysplasia-related bleeding (the OCEAN study): a multicenter randomized controlled trial". Gastroenterology. 166 (4): 690–703. doi:10.1053/j.gastro.2023.12.020.
- ↑ 33.0 33.1 33.2 Sandostatin LAR Depot (octreotide acetate for injectable suspension) prescribing information. Novartis. DailyMed.
- ↑ 34.0 34.1 34.2 Goltstein LCMJ, Grooteman KV, Rocco A; et al. (2021). "Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis". Lancet Gastroenterol Hepatol. 6 (11): 922–932. doi:10.1016/S2468-1253(21)00262-4.
- ↑ 35.0 35.1 35.2 35.3 35.4 Chen H, Wu S, Tang M; et al. (2023). "Thalidomide for recurrent bleeding due to small-intestinal angiodysplasia". N Engl J Med. 389 (18): 1649–1659. doi:10.1056/NEJMoa2303706.
- ↑ 36.0 36.1 36.2 36.3 Thalomid (thalidomide) prescribing information. Bristol Myers Squibb. DailyMed.
- ↑ 37.0 37.1 37.2 37.3 37.4 Laine L (2023). "Management of bleeding due to small-intestinal angiodysplasias". N Engl J Med. 389 (18): 1718–1720. doi:10.1056/NEJMe2310338.
- ↑ DeLoughery TG, Jackson CS, Ko CW, Rockey DC (2024). "AGA clinical practice update on management of iron deficiency anemia: expert review". Clin Gastroenterol Hepatol. 22 (8): 1575–1583. doi:10.1016/j.cgh.2024.03.046.
- ↑ Hakim A, Feuerstein JD (2024). "In small-intestinal angiodysplasia with recurrent bleeding, thalidomide reduced bleeding episodes at 1 y". Ann Intern Med. 177 (3): JC32. doi:10.7326/J24-0005.
```
- SECTION 2: EDITING NOTES
- Changes applied this round**
- **Triage:**
- The BSG/ESGE bullet now says "strongly recommend." The comment notes the grading comes from ACG 2023's summary and still asks for primary sources. - Added the CODE BLUE-J caveat: 25.5% 30-day rebleeding in diverticular bleeding despite an Oakland score ≤8. It also appears in the Summary (item 1) and Uncertainty sections.
- **Whether to reverse at all:** this uncertainty bullet now lists the specific agents ACG–CAG suggests against and its lack of a recommendation on PCC for warfarin, instead of "with any agent." - **Hormonal therapy:**
- Now cites the primary Junquera 2001 RCT. - Adds severe adverse events (2 vs. 1) and the noncirrhotic, whole-GI-tract enrollment. - Summary item 9 now cites Junquera.
- **Thalidomide:**
- The escalation wording now matches Laine ("depending on response and side effects").
- Added the follow-up rebleeding data (20 of 42 patients) and that optimal dose and duration are uncertain.
- Labeled both versions of the earlier trial's figures (Laine vs. Gerson) and its regimen.
- Adverse effects are now split: the RCT's findings (Chen), neuropathy and bradycardia (label), bowel perforation (DeLoughery), possible ischemic heart disease (Hakim).
- **Sequencing note:** adherence added as a reason for using octreotide first (Laine).
- Corrections to the audit's patches**
- DeLoughery 2024 is cited as *Clin Gastroenterol Hepatol* 22(8):1575–1583, following the audit's own reference list. The patch text had it as *Gastroenterology*. - The Junquera and Kinjo references use the full details from the reference list. Kinjo's PMID (39557205) appears only in the audit's patch text, not in its reference list.
- Needs human verification**
- **Bibliographic metadata:** all of it comes from the supplied OpenEvidence lists and has not been independently checked against PubMed. Confirmed PMIDs: HALT-IT. Kinjo's PMID is unconfirmed. - **Thalidomide follow-up data:** the source of the "42 patients, 20 rebled" figure (Chen vs. Laine). A comment in the code flags it. - **Kcentra:** the exact current label wording. - **BSG 2019 and ESGE:** primary sources and grading.
- Remaining placeholders**
- Author/editor template line. - Parent navigation template. - Uncited mechanical VTE prophylaxis line. - Uncited dabigatran CKD point. - BSG/ESGE primary-source comment. - Thalidomide 42/20 verification comment. - Suggested-image comment.